Hairy cell leukemia: short review, today’s recommendations and outlook
Open Access
- 14 February 2014
- journal article
- review article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 4 (2) , e184
Abstract
Hairy cell leukemia (HCL) is part of the low-grade non-Hodgkin lymphoma family and represents approximately 2% of all leukemias. Treatment with splenectomy and interferon-α historically belonged to the first steps of therapeutic options, achieving partial responses/remissions (PR) in most cases with a median survival between 4 and 6 years in the 1980s. The introduction of the purine analogs (PA) pentostatin and cladribine made HCL a well-treatable disease: overall complete response rates (CRR) range from 76 to 98%, with a median disease-free survival (DFS) of 16 years a normal lifespan can be reached and HCL-related deaths are rare. However, insufficient response to PA with poorer prognosis and relapse rates of 30–40% after 5–10 years of follow-up may require alternative strategies. Minimal residual disease can be detected by additional examinations of bone marrow specimens after treatment with PA. The use of immunotherapeutic monoclonal antibodies (mAB) like rituximab as a single agent or in combination with a PA or more recently clinical trials with recombinant immunotoxins (RIT) show promising results to restrict these problems. Recently, the identification of the possible disease-defining BRAF V600E mutation may allow the development of new therapeutic targets.Keywords
This publication has 120 references indexed in Scilit:
- Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemiaHaematologica, 2013
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2012
- Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutationBlood, 2012
- My Treatment Approach to Hairy Cell LeukemiaMayo Clinic Proceedings, 2012
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab PasudotoxClinical Cancer Research, 2011
- BRAFMutations in Hairy-Cell LeukemiaNew England Journal of Medicine, 2011
- Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopesProceedings of the National Academy of Sciences, 2011
- Laparoscopic Splenectomy for Hairy Cell Leukemia in PregnancyCase Reports in Medicine, 2010
- How I treat hairy cell leukemiaBlood, 2010
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2009